[Differentiated antiplatelet therapy for acute coronary syndromes]

Area of Science:

• Cardiology
• Pharmacology

Background:

• Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard post-acute coronary syndromes (ACS) invasive treatment.
• Recent trials (TRITON, PLATO) introduced prasugrel and ticagrelor, prompting re-evaluation of P2Y12 inhibition strategies.

Purpose of the Study:

• To critically review the TRITON and PLATO trial data and subanalyses for prasugrel and ticagrelor versus clopidogrel in ACS patients.
• To provide guidance on clinical decision-making for selecting P2Y12 inhibitors in ACS, particularly in high-risk subgroups.

Main Methods:

• Comparative analysis of pivotal Phase III clinical trials (TRITON and PLATO).
• Examination of study details and subanalyses focusing on efficacy and safety outcomes.
• Review of clinical guidelines and expert recommendations for P2Y12 inhibitor use in ACS.

Main Results:

• Prasugrel and ticagrelor demonstrated improved efficacy over clopidogrel in reducing ischemic events in ACS patients.
• Increased bleeding risk is associated with more potent P2Y12 inhibition, necessitating careful patient selection.
• Subanalyses highlight specific benefits and risks in patients with ST-elevation myocardial infarction (STEMI) and diabetes.

Conclusions:

• The choice of P2Y12 inhibitor in ACS requires balancing ischemic event reduction against bleeding risk.
• Consideration of patient-specific factors, including STEMI and diabetes, is crucial for optimizing DAPT.
• Ongoing research and clinical experience are refining the use of newer P2Y12 inhibitors in ACS management.